- |||||||||| Woulgan (yeast beta-glucan) / ArcticZymes
Review, Journal: Beta-Glucans in Biotechnology: A Holistic Review with a Special Focus on Yeast. (Pubmed Central) - Apr 27, 2025 Finally, this review explores the therapeutic potential of yeast-derived ?-glucans, focusing on their role in immunomodulation and metabolic regulation and their emerging applications in biomedicine, functional foods, and industrial formulations. By synthesizing recent advancements, this work provides insights into the expanding utilization of yeast ?-glucans and their potential for future biotechnological developments.
- |||||||||| Review, Journal: New investigational drugs for Steroid-Refractory Acute Graft-versus-Host disease: a review of the literature. (Pubmed Central) - Jul 8, 2024
While some of these agents have shown encouraging results in early-phase trials, issues such as treatment-related toxicities and inconsistent responses in larger studies highlight the necessity for ongoing research. Current trials exploring new agents and combination therapies offer hope for fulfilling the unmet clinical needs in SR-aGVHD, potentially leading to more effective and precise treatment strategies.
- |||||||||| Begedina (begelomab) / Biotec Pharmacon, Adienne, Regkirona (regdanvimab) / Celltrion
Journal: Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. (Pubmed Central) - Apr 12, 2022 Also, for blocking the primary entry receptor, hACE2, an anti-viral peptide was linked to the Fc region of BsAb that blocks the hACE2 receptor by linker cleavage inside the infected host. Thus, the designed BsAb and anti-viral peptide therapy could be a promising triumvirate way to obstruct the viral entry by blocking the receptor engagement.
- |||||||||| Woulgan (yeast beta-glucan) / Biotec
Journal: Analysis of the proteins secreted by Trichoderma harzianum P49P11 under carbon-limited conditions. (Pubmed Central) - Jun 22, 2021 As far as we know, this is the first work about the continuous synthesis of enzymes under carbon-limited conditions suggesting that different easily assimilated carbon sources can be used to generate different enzymatic cocktails. Each enzyme or uncharacterized protein suggested by shotgun proteomics has the potential to become a promising product for biotechnological applications.
- |||||||||| Woulgan (yeast beta-glucan) / Biotec
Review, Journal: Immunomodulating Effects of Fungal Beta-Glucans: From Traditional Use to Medicine. (Pubmed Central) - May 8, 2021 In addition to these developments related to food uses of beta-glucan-containing supplements, beta-glucans could also hold a novel position in Western medicine as the concept of trained immunity is relatively new and has not been investigated to a large extent. These innovative concepts, together with the emerging success of modern immunological and biotechnological methods, suggest that fungal glucans may play a promising role in both perspectives, and that there are possibilities for traditional medicine to provide an immunological application in both medicine and nutrition.
- |||||||||| Begedina (begelomab) / Biotec, Adienne
Clinical, Journal: Begelomab for severe refractory dermatomyositis: A case report. (Pubmed Central) - Mar 10, 2021 These innovative concepts, together with the emerging success of modern immunological and biotechnological methods, suggest that fungal glucans may play a promising role in both perspectives, and that there are possibilities for traditional medicine to provide an immunological application in both medicine and nutrition. Blockade of DPP-4/CD26, which is expressed on T cells and mediates T cell activation and function, is safe and might be effective in patients with refractory DM.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: The CoV-2 outbreak: how hematologists could help to fight Covid-19. (Pubmed Central) - Jul 1, 2020 We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.
- |||||||||| Woulgan (yeast beta-glucan) / ArcticZymes
Trial completion, Trial completion date, Trial primary completion date: Evaluation of Woulgan in Diabetic Foot Ulcer (clinicaltrials.gov) - May 30, 2019 P4, N=62, Completed, A possible combined treatment algorithm for COVID-19 is here proposed. Recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Dec 2018
- |||||||||| Woulgan (yeast beta-glucan) / ArcticZymes
Trial primary completion date: Evaluation of Woulgan in Diabetic Foot Ulcer (clinicaltrials.gov) - Feb 1, 2018 P4, N=80, Recruiting, Recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Dec 2018 Trial primary completion date: Oct 2017 --> Oct 2018
- |||||||||| Begedina (begelomab) / Adienne
Trial termination, Trial primary completion date, IO biomarker: Study of BEGEDINA (clinicaltrials.gov) - Sep 21, 2017 P3, N=36, Terminated, Trial primary completion date: Oct 2017 --> Oct 2018 Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Jul 2017; Insufficient rate of accrual
- |||||||||| Begedina (begelomab) / Adienne
Enrollment closed, Enrollment change, IO biomarker: Study of BEGEDINA (clinicaltrials.gov) - Jun 22, 2017 P3, N=36, Active, not recruiting, Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Jul 2017; Insufficient rate of accrual Recruiting --> Active, not recruiting | N=184 --> 36
- |||||||||| Begedina (begelomab) / Adienne
Enrollment open, IO biomarker: Study of BEGEDINA (clinicaltrials.gov) - Jun 18, 2016 P3, N=184, Recruiting, Recruiting --> Active, not recruiting | N=184 --> 36 Not yet recruiting --> Recruiting
- |||||||||| Begedina (begelomab) / Adienne
Trial initiation date, Trial primary completion date, IO biomarker: Study of BEGEDINA (clinicaltrials.gov) - Jul 15, 2015 P3, N=184, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Sep 2017 --> Feb 2018
- |||||||||| Begedina (begelomab) / Adienne
New P3 trial, IO biomarker: Study of BEGEDINA (clinicaltrials.gov) - Apr 8, 2015 P3, N=186, Not yet recruiting,
|